Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Living clinical practice guideline on drugs for type 2 diabetes mellitus
EF 2022-23
Résumé
Why this research is important: Diabetes affects half a billion people worldwide, is the ninth leading cause of death internationally, and is associated with significant cardiovascular and kidney-related complications. Several medications in recent years (SGLT-2 inhibitors and GLP-1 receptor agonists) have demonstrated cardiovascular and kidney-related protective effects. Newer medications, supported by major international studies, have now emerged as potential therapies.
Rapidly evolving evidence warrants dynamically updated systematic reviews summarizing the body of evidence, and trustworthy living guidelines that are able to reflect latest available evidence.
Proposed research: The focus of this research is to produce a trustworthy living clinical practice guideline to inform diabetes management internationally.
Guideline development will involve: (1) recruitment of a coordinating team; (2) recruitment of a guideline panel including patient partners, clinical experts and methodologists; (3) partnership with professional societies; (4) identification of guideline questions and outcomes to be addressed; (5) coordination of the living systematic review and network meta-analysis to address prioritized clinical questions; (6) panel meetings to move from evidence to recommendations using GRADE; (7) drafting, editing and approval of the guideline with input from panel members and professional societies; and (8) monitoring for new, potentially practice-changing evidence warranting updates to the systematic review and guideline.
Potential impact: Findings and guidance will be disseminated internationally via the British Medical Journal (accessing an international readership) and MAGICapp (online, interactive platform for dissemination of evidence and guidance).
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486511
Name
Agarwal Arnav
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Living clinical practice guideline on drugs for type 2 diabetes mellitus
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Practice Guideline; Living Guideline; Living Network Meta-Analysis; Living Systematic Review; Pharmacotherapy; Type 2 Diabetes
Abstract
Why this research is important: Diabetes affects half a billion people worldwide, is the ninth leading cause of death internationally, and is associated with significant cardiovascular and kidney-related complications. Several medications in recent years (SGLT-2 inhibitors and GLP-1 receptor agonists) have demonstrated cardiovascular and kidney-related protective effects. Newer medications, supported by major international studies, have now emerged as potential therapies.
Rapidly evolving evidence warrants dynamically updated systematic reviews summarizing the body of evidence, and trustworthy living guidelines that are able to reflect latest available evidence.
Proposed research: The focus of this research is to produce a trustworthy living clinical practice guideline to inform diabetes management internationally.
Guideline development will involve: (1) recruitment of a coordinating team; (2) recruitment of a guideline panel including patient partners, clinical experts and methodologists; (3) partnership with professional societies; (4) identification of guideline questions and outcomes to be addressed; (5) coordination of the living systematic review and network meta-analysis to address prioritized clinical questions; (6) panel meetings to move from evidence to recommendations using GRADE; (7) drafting, editing and approval of the guideline with input from panel members and professional societies; and (8) monitoring for new, potentially practice-changing evidence warranting updates to the systematic review and guideline.
Potential impact: Findings and guidance will be disseminated internationally via the British Medical Journal (accessing an international readership) and MAGICapp (online, interactive platform for dissemination of evidence and guidance).
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Agarwal, Arnav
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~